title: Impact of angiographic peri-stent contrast staining (PSS) on late adverse events after sirolimus-eluting stent implantation: an observation from the multicenter j-Cypher registry PSS substudy.
abstract: This study sought to assess clinical significance of angiographic peri-stent contrast staining (PSS) after sirolimus-eluting stent (SES) implantation in a large multicenter study with 5-year follow-up. The j-Cypher PSS substudy is a multicenter study including 5712 patients (7838 lesions) who underwent follow-up angiographic study within 12 months after SES implantation. Late acquired PSS was observed in 184 patients (3.2 %) or 194 lesions (2.5 %). Independent risk factors of PSS were chronic total occlusion and left anterior descending artery lesion, while negative risk factors were in-stent restenosis, diabetes mellitus, ≥70 years of age, and left circumflex coronary artery lesion. Cumulative incidence of definite very late stent thrombosis (VLST) at 4 years after the index follow-up angiography in lesions with PSS was significantly higher than that in lesions without PSS (5.3 versus 0.7 %, P < 0.0001). Late target-lesion revascularization (TLR) was also more frequently observed in the PSS group (13 versus 6.9 %, P = 0.01), while late TLR for restenosis excluding those TLR procedures for VLST tended to be higher in the PSS group (9.9 versus 6.3 %; P = 0.15). PSS found in 2.5 % of lesions within 12 months after SES implantation was associated with higher risk for subsequent VLST.
authors: Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, 54 Shougoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
authors: Masao
authors: M
authors: Imai
authors: Takeshi
authors: T
authors: Kimura
authors: Takeshi
authors: T
authors: Morimoto
authors: Naritatsu
authors: N
authors: Saito
authors: Hiroki
authors: H
authors: Shiomi
authors: Ren
authors: R
authors: Kawaguchi
authors: Hakuken
authors: H
authors: Kan
authors: Hiroaki
authors: H
authors: Mukawa
authors: Hiroshi
authors: H
authors: Fujita
authors: Takuo
authors: T
authors: Ishise
authors: Fujio
authors: F
authors: Hayashi
authors: Kazuya
authors: K
authors: Nagao
authors: Shunsuke
authors: S
authors: Take
authors: Hiromasa
authors: H
authors: Taniguchi
authors: Hiroki
authors: H
authors: Sakamoto
authors: Takafumi
authors: T
authors: Yamane
authors: Kinya
authors: K
authors: Shirota
authors: Hiromichi
authors: H
authors: Tamekiyo
authors: Takayuki
authors: T
authors: Okamura
authors: Koichi
authors: K
authors: Kishi
authors: Shinichirou
authors: S
authors: Miyazaki
authors: Satoshi
authors: S
authors: Yamamoto
authors: Kyohei
authors: K
authors: Yamaji
authors: Tomohiro
authors: T
authors: Kawasaki
authors: Eiji
authors: E
authors: Taguchi
authors: Hitoshi
authors: H
authors: Nakajima
authors: Ippei
authors: I
authors: Kosedo
authors: Takeshi
authors: T
authors: Tada
authors: Kazushige
authors: K
authors: Kadota
authors: Kazuaki
authors: K
authors: Mitsudo
mesh_terms: D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019917:Blood Vessel Prosthesis Implantation / Q000009:adverse effects / Q000379:methods; D003287:Contrast Media / Q000009:adverse effects*; D017023:Coronary Angiography / Q000009:adverse effects* / Q000379:methods; D023903:Coronary Restenosis / Q000517:prevention & control; D023921:Coronary Stenosis / Q000601:surgery; D003328:Coronary Thrombosis / Q000209:etiology; D054855:Drug-Eluting Stents / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007564:Japan; D008297:Male; D012042:Registries; D012189:Retrospective Studies; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D003287:Contrast Media; D020123:Sirolimus